Results 131 to 140 of about 286,453 (328)

Supporting long‐term engagement in HIV clinical care: Learning from the COVID‐19 pandemic

HIV Medicine, EarlyView.
Abstract Objectives SHIELD is a London‐based study of engagement in HIV clinical care during and after the COVID‐19 pandemic. We document the characteristics of service users who either re‐engaged or disengaged with HIV care, together with reflections of HIV clinical service‐providers to inform recommendations that address care retention for the long ...
R. Dhairyawan, Sara Paparini, M. Smuk, S. Sidat, R. Mbewe, Silvia Petretti, V. Martin, S. Dakshina, H. Alexander, T. D. Appleby, K. Childs, M. Bracchi, B. Dragovic, G. Haidari, N. Mackie, I. Reeves, A. Umaipalan, L. J. Waters, J. Anderson, C. M. Orkin   +19 more
wiley   +1 more source

Validation of prognostic scores in patients with HIV‐related diffuse large B‐cell lymphoma: The value of peripheral blood parameters—A study from the Spanish Lymphoma Group GELTAMO

British Journal of Haematology, EarlyView.
Maria Huguet, Mireia Morgades, Alfredo Rivas‐Delgado, Mariana Bastos‐Oreiro, Raúl Córdoba, Antonio Salar, Fátima de la Cruz‐Vicente, Miguel Alcoceba, Blanca Ferrer‐Lores, Ana Jiménez‐Ubieto, Antonio Gutiérrez, María Infante, Sofía Huerga, Pau Abrisqueta, David Cruz, Carlos Montalbán, Ana Muntañola, Sonia González‐de Villambrosia, Josep‐Maria Ribera, José‐Tomás Navarro   +19 more
wiley   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Psychological responses to interval and continuous exercise in people living with HIV: A single‐blind, counterbalanced, crossover study

HIV Medicine, EarlyView.
Abstract Aim This study compared acute psychological responses to a single session of low‐volume high‐intensity interval exercise (HIIE‐LV), high‐volume high‐intensity interval exercise (HIIE‐HV), and moderate‐intensity continuous exercise (MICE) in people living with HIV, and healthy controls using a randomized, counterbalanced crossover design ...
Phelipe Wilde, Victor S. de Queiros, Jason R. Jaggers, Angelo Sabag, Júlio M. Alves, Elaine Fernandes, Roberto F. C. Rocha, Paulo F. de Almeida‐Neto, Ronaldo Vagner Thomatieli‐Santos, Paulo Moreira Silva Dantas   +9 more
wiley   +1 more source

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

HIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre, Antoine Gross, Alain Makinson   +2 more
wiley   +1 more source

Hierarchical analysis of unsuccessful tuberculosis treatment among people living with HIV in Brazil using nationwide surveillance data

HIV Medicine, EarlyView.
Abstract Introduction People with tuberculosis‐HIV coinfection face multiple barriers to effective treatment, including social vulnerability, stigma and limited access to healthcare. This study examined factors associated with loss to follow‐up and death among individuals with tuberculosis‐HIV in Brazil.
Lucas Vinícius de Lima, Gabriel Pavinati, Francisco Beraldi‐Magalhães, Rubia Laine de Paula Andrade‐Gonçalves, Aline Aparecida Monroe, Marcela Demitto Furtado, Rosana Rosseto de Oliveira, Daniele Maria Pelissari, Kleydson Bonfim Andrade Alves, Gabriela Tavares Magnabosco   +9 more
wiley   +1 more source

Delays by people living with HIV/AIDS in accessing antiretroviral therapy [PDF]

, 2013
Diriisa Semakula, Claire Van Deventer
openalex   +1 more source

Human Immunodeficiency Virus (HIV) Treatment With Antiretroviral Therapy Mitigates the High Risk of Mental Health Disorders Associated With HIV Infection in the US Population [PDF]

, 2023
Djibril M. Ba, Kathryn Risher, Paddy Ssentongo, Yue Zhang, Qi Dai, Guodong Liu, Mamoudou Maïga, Xuehong Zhang, Brehima Diakité, Souleymane Coulibaly, Lifang Hou, Douglas Leslie, Vernon M. Chinchilli   +12 more
openalex   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source